STAT+: Merck-Kelun Lung Cancer Drug Cut Risk of Tumor Progression by 65%, ASCO Abstract Shows

Why It Matters

A 65% reduction in progression could reshape first‑line NSCLC treatment and validates cross‑border biotech collaborations, accelerating access to innovative therapies worldwide.

Key Takeaways

• Sac‑TMT cut tumor progression risk by 65% in Phase 3 trial
• First ADC‑PD‑1 combo approved for untreated advanced NSCLC
• Preliminary overall survival trend favors sac‑TMT, pending longer follow‑up
• Partnership highlights Chinese innovation entering global oncology market

Pulse Analysis

Non‑small cell lung cancer remains the leading cause of cancer death, with first‑line therapy dominated by platinum chemotherapy, PD‑1 inhibitors, and, more recently, antibody‑drug conjugates (ADCs). ADCs deliver cytotoxic payloads directly to tumor cells, improving efficacy while limiting systemic toxicity. Combining an ADC with a PD‑1 checkpoint blocker leverages complementary mechanisms—direct tumor killing and immune activation—offering a logical next step in treatment intensification. The sac‑TMT regimen, which pairs a sacituzumab‑based ADC with a PD‑1 inhibitor, exemplifies this strategy and reflects a broader industry shift toward multimodal regimens that can overcome resistance pathways.

The Phase 3 trial enrolled over 600 Chinese patients with previously untreated, advanced NSCLC and demonstrated a 65% relative reduction in disease progression compared with standard therapy. Although overall‑survival data remain immature, an early trend suggests a possible survival advantage, prompting optimism among oncologists. Regulatory implications are significant: Merck may seek accelerated approval in China first, leveraging local data, before pursuing submissions in the United States and Europe. The trial’s success also underscores the growing credibility of Chinese clinical research, which is increasingly meeting international standards and providing a platform for global drug development.

Beyond the clinical data, the partnership between Merck and Kelun‑Biotech signals a maturing ecosystem where Western pharma taps Chinese innovation to diversify pipelines. Investors are likely to view this collaboration as a template for future co‑development deals, especially as China’s biotech sector matures and its domestic market expands. If sac‑TMT achieves global approval, it could generate billions in revenue, reshape NSCLC treatment algorithms, and accelerate the adoption of ADC‑immunotherapy combos across oncology.